4//SEC Filing
Torley Helen 4
Accession 0001159036-25-000054
CIK 0001159036other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 6:54 PM ET
Size
28.5 KB
Accession
0001159036-25-000054
Insider Transaction Report
Form 4
Torley Helen
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-11-12$71.67/sh−498$35,690→ 733,719 total - Exercise/Conversion
Common Stock
2025-11-11$8.11/sh+20,000$162,200→ 753,719 total - Sale
Common Stock
2025-11-12$71.09/sh−6,784$482,268→ 734,217 total - Sale
Common Stock
2025-11-11$68.80/sh−4,000$275,180→ 745,219 total - Sale
Common Stock
2025-11-11$69.73/sh−11,500$801,906→ 733,719 total - Exercise/Conversion
Common Stock
2025-11-12$8.11/sh+20,000$162,200→ 753,719 total - Exercise/Conversion
Option to Purchase Common Stock
2025-11-10$8.11/sh−20,000$162,200→ 56,569 totalExercise: $8.11Exp: 2026-02-03→ Common Stock (20,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock
2025-11-11$8.11/sh−20,000$162,200→ 36,569 totalExercise: $8.11Exp: 2026-02-03→ Common Stock (20,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock
2025-11-12$8.11/sh−20,000$162,200→ 16,569 totalExercise: $8.11Exp: 2026-02-03→ Common Stock (20,000 underlying) - Sale
Common Stock
2025-11-10$68.71/sh−19,900$1,367,409→ 733,819 total - Sale
Common Stock
2025-11-10$69.30/sh−100$6,930→ 733,719 total - Sale
Common Stock
2025-11-11$67.89/sh−4,500$305,514→ 749,219 total - Sale
Common Stock
2025-11-12$70.22/sh−12,718$893,033→ 741,001 total - Exercise/Conversion
Common Stock
2025-11-10$8.11/sh+20,000$162,200→ 753,719 total
Footnotes (9)
- [F1]The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.
- [F2]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.250 to $69.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.395 to $68.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.400 to $69.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $69.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.570 to $70.565. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.570 to $71.560. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F8]Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.575 to $71.730. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.
Documents
Issuer
HALOZYME THERAPEUTICS, INC.
CIK 0001159036
Entity typeother
Related Parties
1- filerCIK 0001528185
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 6:54 PM ET
- Size
- 28.5 KB